ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
69,298.75
-0.01%
S&P 500
5,346.99
-0.11%
Dow Jones
38,798.99
-0.22%
US Dollar vs Yen
156.7275
0.00%
Brent Oil
79.395
0.00%
Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Blueprint Medicines Corporation (BPMC)

  7. Blueprint Medicines Corporation (BPMC) ニュース

BPMC

Blueprint Medicines (BPMC)

Blueprint Medicines Corporation
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:BPMC
日付受信時刻ニュースソース見出しコード企業名
2024/06/0805 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
2024/06/0705 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
2024/06/0606 : 11Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
2024/06/0605 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
2024/06/0505 : 40Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
2024/06/0505 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
2024/06/0405 : 28Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
2024/06/0105 : 38Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
2024/05/3107 : 01PR Newswire (US)Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib)NASDAQ:BPMCBlueprint Medicines Corporation
2024/05/2421 : 00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BPMCBlueprint Medicines Corporation
2024/05/2406 : 05PR Newswire (US)Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual MeetingNASDAQ:BPMCBlueprint Medicines Corporation
2024/05/1805 : 05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
2024/05/1805 : 05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
2024/05/1606 : 07Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
2024/05/1606 : 05Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
2024/05/1105 : 05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
2024/05/0706 : 26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
2024/05/0706 : 19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
2024/05/0705 : 01PR Newswire (US)Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BPMCBlueprint Medicines Corporation
2024/05/0220 : 00PR Newswire (US)Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue GuidanceNASDAQ:BPMCBlueprint Medicines Corporation
2024/04/1821 : 00PR Newswire (US)Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024NASDAQ:BPMCBlueprint Medicines Corporation
2024/04/1121 : 00PR Newswire (US)Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted TherapeuticsNASDAQ:BPMCBlueprint Medicines Corporation
2024/04/0505 : 01PR Newswire (US)Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BPMCBlueprint Medicines Corporation
2024/03/1207 : 27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
2024/03/1207 : 26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
2024/03/1207 : 24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
2024/03/1207 : 23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
2024/03/1207 : 21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
2024/03/1207 : 20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
2024/03/1207 : 19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BPMCBlueprint Medicines Corporation
 Showing the most relevant articles for your search:NASDAQ:BPMC

最近閲覧した銘柄

EU
IMI13
Lyxor MI13 iNav
EU
B349
Kingdom of Belgium 1.625...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有